Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

WJOG6510G : Randomized phase II study of panitumumab + irinotecan versus cetuximab + irinotecan in Patients Wild-Type KRAS Metastatic Colorectal Cancer Following Treatment with Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy

ABSTRACT: Interventions: Panitumumab + Irinotecan Cetuximab + Irinotecan Primary outcome(s): Progression free survival Study Design: Parallel Randomized

DISEASE(S): Advanced Colorectal Cancer

PROVIDER: 2622071 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.

Project description: Not available

| S-EPMC3699713 | biostudies-literature

MicroRNA expression profiling identified miR-31-5p/3p as associated with time to progression in wild-type KRAS metastatic colorectal cancer treated with cetuximab but not panitumumab

Project description:The aim of our study was to investigate whether miRNAs could serve as predictive biomarkers to anti-EGFR therapy (cetuximab, panitumumab) in patients with KRAS wild-type (wt-KRAS) metastatic colorectal cancer (mCRC). In our study, historical cohort of 96 patiens with wt-KRAS mCRC (2006-2009) was included and further divided into exploratory and validation cohorts. Large-scale miRNAs expression profiling was performed on the exploratory cohort of 41 wt-KRAS mCRC patients treated with cetuximab to identify miRNAs associated with time to progression (TTP). The validation was performed on two independent cohorts: 30 patients of wt-KRAS mCRC treated with cetuximab and 25 patients of wt-KRAS mCRC treated with panitumumab.

2016-05-05 | E-MTAB-3548 | biostudies-arrayexpress

A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients.

Project description: Not available

| S-EPMC6738054 | biostudies-literature

CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial.

Project description: Not available

| S-EPMC6534840 | biostudies-literature

Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.

Project description: Not available

| S-EPMC4371780 | biostudies-literature

Randomized phase II study of biweekly cetuximab versus panitumumab in patients not combination of irinotecan wild-type KRAS metastatic colorectal cancer following treatment with fluoropyrimidine and oxaliplatin chemotherapy

Project description:Interventions: panitumumab cetuximab Primary outcome(s): overall survival Study Design: Parallel Randomized

| 2622321 | ecrin-mdr-crc

Phase II clinical trial of third-line Panitumumab and irinotecan or Panitumumab therapy for patients with KRAS wild-type unresectable/recurrent colorectal cancer

Project description:Interventions: Chemotherapy (Panitumumab + irinotecan or panitumumab) Primary outcome(s): Response rate of Panitumumab + irinotecan regimen Study Design: Single arm Non-randomized

| 2620093 | ecrin-mdr-crc

Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA)

Project description:The purpose of the study is to evaluate the efficacy and safety of the combination of Panitumumab with Irinotecan in patients with Wild-Type KRAS metastatic colorectal cancer refractory to irinotecan based chemotherapy.

| 2076606 | ecrin-mdr-crc

WJOG6510GTR: Study of genetic biomarkers to predict efficacy in patients with wild-type KRAS metastatic colorectal cancer receiving Panitumumab + Irinotecan or Cetuximab + Irinotecan

Project description:Primary outcome(s): To evaluate the correlation between the efficacy or safety and the genetic polymorphism in patients with cetuximab plus irinotecan or panitumumab plus irinotecan therapy.

| 2624189 | ecrin-mdr-crc

Multicenter Phase II Study of Panitumumab and Irinotecan with or without Fluoropyrimidines in patients with KRAS Wild-type Metastatic Colorectal Cancer (PACIFIC)

Project description:Interventions: Irinotecan 150 mg/m2/biweekly div l-LV 200mg/m2/biweekly div 5-FU/bolus 400mg/m2/biweekly div (bolus) 5-FU/infusional 2,400mg/m2/biweekly div Panitumumab 6mg/kg/biweekly div or S-1 80mg/m2/day p.o. day 1-7 Irinotecan 150mg/m2 day 1 Panitumumab 6mg/kg/biweekly div Irinotecan 150mg/m2/ biweekly div Panitumumab 6mg/kg/biweekly div Primary outcome(s): Progression-free survival Study Design: Parallel Randomized

| 2623074 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data